Personalizing health care: feasibility and future implications.
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into impr...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2013
|
| _version_ | 1826284603578515456 |
|---|---|
| author | Godman, B Finlayson, A Cheema, P Zebedin-Brandl, E Gutiérrez-Ibarluzea, I Jones, J Malmström, R Asola, E Baumgärtel, C Bennie, M Bishop, I Bucsics, A Campbell, S Diogene, E Ferrario, A Fürst, J Garuoliene, K Gomes, M Harris, K Haycox, A Herholz, H Hviding, K Jan, S Kalaba, M Kvalheim, C Laius, O Lööv, SA Malinowska, K Martin, A McCullagh, L Nilsson, F Paterson, K Schwabe, U Selke, G Sermet, C Simoens, S Tomek, D Vlahovic-Palcevski, V Voncina, L Wladysiuk, M van Woerkom, M Wong-Rieger, D Zara, C Ali, R Gustafsson, L |
| author_facet | Godman, B Finlayson, A Cheema, P Zebedin-Brandl, E Gutiérrez-Ibarluzea, I Jones, J Malmström, R Asola, E Baumgärtel, C Bennie, M Bishop, I Bucsics, A Campbell, S Diogene, E Ferrario, A Fürst, J Garuoliene, K Gomes, M Harris, K Haycox, A Herholz, H Hviding, K Jan, S Kalaba, M Kvalheim, C Laius, O Lööv, SA Malinowska, K Martin, A McCullagh, L Nilsson, F Paterson, K Schwabe, U Selke, G Sermet, C Simoens, S Tomek, D Vlahovic-Palcevski, V Voncina, L Wladysiuk, M van Woerkom, M Wong-Rieger, D Zara, C Ali, R Gustafsson, L |
| author_sort | Godman, B |
| collection | OXFORD |
| description | Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. |
| first_indexed | 2024-03-07T01:16:19Z |
| format | Journal article |
| id | oxford-uuid:8ed0004f-3af6-4a51-b046-dcbf65f97ad1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:16:19Z |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:8ed0004f-3af6-4a51-b046-dcbf65f97ad12022-03-26T23:00:20ZPersonalizing health care: feasibility and future implications.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8ed0004f-3af6-4a51-b046-dcbf65f97ad1EnglishSymplectic Elements at OxfordBioMed Central2013Godman, BFinlayson, ACheema, PZebedin-Brandl, EGutiérrez-Ibarluzea, IJones, JMalmström, RAsola, EBaumgärtel, CBennie, MBishop, IBucsics, ACampbell, SDiogene, EFerrario, AFürst, JGaruoliene, KGomes, MHarris, KHaycox, AHerholz, HHviding, KJan, SKalaba, MKvalheim, CLaius, OLööv, SAMalinowska, KMartin, AMcCullagh, LNilsson, FPaterson, KSchwabe, USelke, GSermet, CSimoens, STomek, DVlahovic-Palcevski, VVoncina, LWladysiuk, Mvan Woerkom, MWong-Rieger, DZara, CAli, RGustafsson, LConsiderable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. |
| spellingShingle | Godman, B Finlayson, A Cheema, P Zebedin-Brandl, E Gutiérrez-Ibarluzea, I Jones, J Malmström, R Asola, E Baumgärtel, C Bennie, M Bishop, I Bucsics, A Campbell, S Diogene, E Ferrario, A Fürst, J Garuoliene, K Gomes, M Harris, K Haycox, A Herholz, H Hviding, K Jan, S Kalaba, M Kvalheim, C Laius, O Lööv, SA Malinowska, K Martin, A McCullagh, L Nilsson, F Paterson, K Schwabe, U Selke, G Sermet, C Simoens, S Tomek, D Vlahovic-Palcevski, V Voncina, L Wladysiuk, M van Woerkom, M Wong-Rieger, D Zara, C Ali, R Gustafsson, L Personalizing health care: feasibility and future implications. |
| title | Personalizing health care: feasibility and future implications. |
| title_full | Personalizing health care: feasibility and future implications. |
| title_fullStr | Personalizing health care: feasibility and future implications. |
| title_full_unstemmed | Personalizing health care: feasibility and future implications. |
| title_short | Personalizing health care: feasibility and future implications. |
| title_sort | personalizing health care feasibility and future implications |
| work_keys_str_mv | AT godmanb personalizinghealthcarefeasibilityandfutureimplications AT finlaysona personalizinghealthcarefeasibilityandfutureimplications AT cheemap personalizinghealthcarefeasibilityandfutureimplications AT zebedinbrandle personalizinghealthcarefeasibilityandfutureimplications AT gutierrezibarluzeai personalizinghealthcarefeasibilityandfutureimplications AT jonesj personalizinghealthcarefeasibilityandfutureimplications AT malmstromr personalizinghealthcarefeasibilityandfutureimplications AT asolae personalizinghealthcarefeasibilityandfutureimplications AT baumgartelc personalizinghealthcarefeasibilityandfutureimplications AT benniem personalizinghealthcarefeasibilityandfutureimplications AT bishopi personalizinghealthcarefeasibilityandfutureimplications AT bucsicsa personalizinghealthcarefeasibilityandfutureimplications AT campbells personalizinghealthcarefeasibilityandfutureimplications AT diogenee personalizinghealthcarefeasibilityandfutureimplications AT ferrarioa personalizinghealthcarefeasibilityandfutureimplications AT furstj personalizinghealthcarefeasibilityandfutureimplications AT garuolienek personalizinghealthcarefeasibilityandfutureimplications AT gomesm personalizinghealthcarefeasibilityandfutureimplications AT harrisk personalizinghealthcarefeasibilityandfutureimplications AT haycoxa personalizinghealthcarefeasibilityandfutureimplications AT herholzh personalizinghealthcarefeasibilityandfutureimplications AT hvidingk personalizinghealthcarefeasibilityandfutureimplications AT jans personalizinghealthcarefeasibilityandfutureimplications AT kalabam personalizinghealthcarefeasibilityandfutureimplications AT kvalheimc personalizinghealthcarefeasibilityandfutureimplications AT laiuso personalizinghealthcarefeasibilityandfutureimplications AT loovsa personalizinghealthcarefeasibilityandfutureimplications AT malinowskak personalizinghealthcarefeasibilityandfutureimplications AT martina personalizinghealthcarefeasibilityandfutureimplications AT mccullaghl personalizinghealthcarefeasibilityandfutureimplications AT nilssonf personalizinghealthcarefeasibilityandfutureimplications AT patersonk personalizinghealthcarefeasibilityandfutureimplications AT schwabeu personalizinghealthcarefeasibilityandfutureimplications AT selkeg personalizinghealthcarefeasibilityandfutureimplications AT sermetc personalizinghealthcarefeasibilityandfutureimplications AT simoenss personalizinghealthcarefeasibilityandfutureimplications AT tomekd personalizinghealthcarefeasibilityandfutureimplications AT vlahovicpalcevskiv personalizinghealthcarefeasibilityandfutureimplications AT voncinal personalizinghealthcarefeasibilityandfutureimplications AT wladysiukm personalizinghealthcarefeasibilityandfutureimplications AT vanwoerkomm personalizinghealthcarefeasibilityandfutureimplications AT wongriegerd personalizinghealthcarefeasibilityandfutureimplications AT zarac personalizinghealthcarefeasibilityandfutureimplications AT alir personalizinghealthcarefeasibilityandfutureimplications AT gustafssonl personalizinghealthcarefeasibilityandfutureimplications |